Alcon announces closing of acquisition of Belkin Vision

News
Article

Belkin Vision is the developer of Vision Eagle direct selective laser trabeculoplasty technology.

Business meeting in office Image Credit: AdobeStock/alfa27

Image Credit: AdobeStock/alfa27

Alcon has announced completion of its acquisition of Belkin Vision, developer of the Belkin Vision Eagle direct selective laser trabeculoplasty (DSLT) for the treatment of glaucoma. The companies have agreed to a total upfront consideration of $81 million USD, including a cash payment of approximately $65 million, according to a news release. The deal also includes the potential for up to $385 million in payments, which is contingent on sales-based milestones.1

“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, president of Global Surgical Franchise at Alcon, in the release. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”

The acquisition includes the DSLT technology, which works in a similar fashion to traditional SLT by delivering laser energy to the trabecular meshwork. DSLT technology, however, includes proprietary eye-tracking technology for accurate, automated treatment delivery through the limbus, which eliminates the needs for a gonio lens or manual aiming, according to the release.1

“Despite ample evidence for SLT as primary therapy in glaucoma treatment, practical challenges limit availability to many patients who could benefit from it,” said Nathan M. Radcliffe, MD, in the release. “DSLT will have a profound impact on laser-first, helping to overcome these barriers and meaningfully improve access to laser therapy — shifting doctor and patient perceptions around efficiency and comfort.”

Belkin’s DSLT technology has been approved in the EU and UK, and has receive 510(k) clearance from the US FDA, but is not available yet in the US. Alcon plans to continue supplying DSLT technology in the EU and UK and aims to have the device available to eye care providers in the US by the end of 2024.1

References:
  1. Alcon completes acquisition of Belkin Vision, expanding glaucoma portfolio with direct selective laser trabeculoplasty (DSLT) device. Alcon. July 1, 2024. Accessed July 2, 2024. https://www.alcon.com/media-release/alcon-completes-acquisition-belkin-vision-expanding-glaucoma-portfolio-direct
Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.